{
    "nctId": "NCT01209195",
    "briefTitle": "A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers",
    "officialTitle": "A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Cytological or histological confirmation of locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or endometrial cancer; OR, cytological or histological confirmation of locally advanced /metastatic Her2 non-overexpressing breast cancer\n* Eighteen years of age or above\n* Candidates for chemotherapy\n* Able to understand and sign an informed consent (or have a legal representative who is able to do so)\n* Measurable disease according to RECIST v1.1\n* ECOG Performance Score (PS) of \u2264 2\n* Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121\n\nExclusion Criteria:\n\n* Prior radiation therapy to \\>25% of bone marrow-bearing areas\n* Evidence of any other active malignancy\n* Active infection or fever\\> 38.5\u00b0C during screening visits or on the first scheduled day of dosing\n* Symptomatic CNS disease\n* Known hypersensitivity to any of the components of MM-121 or who have had hypersensitivity reactions to fully human monoclonal antibodies\n* Received treatment, within 30 days prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state\n* Pregnant or breast feeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}